全文获取类型
收费全文 | 2365篇 |
免费 | 195篇 |
国内免费 | 152篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 41篇 |
妇产科学 | 11篇 |
基础医学 | 190篇 |
口腔科学 | 16篇 |
临床医学 | 257篇 |
内科学 | 384篇 |
皮肤病学 | 39篇 |
神经病学 | 70篇 |
特种医学 | 72篇 |
外科学 | 159篇 |
综合类 | 657篇 |
预防医学 | 40篇 |
眼科学 | 37篇 |
药学 | 455篇 |
中国医学 | 246篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 4篇 |
2022年 | 5篇 |
2021年 | 19篇 |
2020年 | 11篇 |
2019年 | 22篇 |
2018年 | 22篇 |
2017年 | 36篇 |
2016年 | 25篇 |
2015年 | 35篇 |
2014年 | 68篇 |
2013年 | 137篇 |
2012年 | 89篇 |
2011年 | 86篇 |
2010年 | 80篇 |
2009年 | 109篇 |
2008年 | 117篇 |
2007年 | 134篇 |
2006年 | 158篇 |
2005年 | 166篇 |
2004年 | 143篇 |
2003年 | 135篇 |
2002年 | 155篇 |
2001年 | 145篇 |
2000年 | 153篇 |
1999年 | 141篇 |
1998年 | 130篇 |
1997年 | 118篇 |
1996年 | 97篇 |
1995年 | 62篇 |
1994年 | 27篇 |
1993年 | 22篇 |
1992年 | 22篇 |
1991年 | 14篇 |
1990年 | 18篇 |
1989年 | 6篇 |
1988年 | 1篇 |
排序方式: 共有2712条查询结果,搜索用时 15 毫秒
91.
《Expert opinion on pharmacotherapy》2013,14(6):875-887
Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. With the widespread use of PSA (prostate specific antigen), recurrent disease after local treatment for localised prostate cancer is usually diagnosed long before evidence of metastatic disease. In many cases, hormonal manipulations are started at the time of biochemical relapse and therefore, patients become ‘hormone refractory’ earlier in the course of their disease, frequently with a good performance status, often with no evidence of metastatic disease, and they still face a considerably long life expectancy. Despite these changes, the need for more options in the treatment of HRPC is obvious. The pharmacological treatments that are in use and those that are under investigation for this group of patients will be discussed and include: cytotoxic agents including the microtubule inhibitors, alone and in combination with other conventional or experimental therapies such as calcitriol or thalidomide; treatment with epothilone analogues; endothelin receptor antagonists; palliative therapy with bisphosphonates, bone-targeted radiopharmaceuticals and other developing treatments such as vaccines, gene therapies and monoclonal antibodies. 相似文献
92.
《Expert opinion on pharmacotherapy》2013,14(10):1585-1596
Introduction: Endothelin is a key mediator in the pathophysiology of pulmonary arterial hypertension (PAH). Its effects are mediated through the activation of two associated receptor subtypes, termed A and B. Therapeutic strategies that modulate the activity of endothelin are, therefore, of interest to improve the functional status of patients with PAH. Areas covered: The rationale for the use of endothelin receptor antagonists as a therapeutic class in PAH and pertinent data from important clinical studies are presented in this review. Areas for future research are also suggested. Expert opinion: The availability of the endothelin receptor antagonist class of agents represents a significant addition to the therapeutic armamentarium which is available for the treatment of PAH. Comparative studies are warranted to establish whether selective endothelin-A receptor antagonism is more advantageous than dual receptor antagonism. Future studies of endothelin receptor antagonists will increasingly focus on the potential of a combination of different PAH therapeutic classes and will employ ‘harder’ clinical end points. This is of crucial importance to ensure that future developments are both worthwhile and acceptable to patients, physicians, health system payers and regulatory authorities. 相似文献
93.
《Expert opinion on investigational drugs》2013,22(11):2579-2592
Acute renal failure (ARF) occurs frequently in hospitalised patients and is associated with significant morbidity and mortality. Many therapeutic strategies have been undertaken both to prevent acute renal injury and, once ARF occurs, to improve renal function and reduce mortality. Among the available pharmacological options, no specific therapy has been shown to alter the course of ARF. This article reviews the efficacy of several strategies in experimental renal disease and raises the possibility that similar interventions might be available to the clinician in the near future for the prevention and management of ARF. The prospect of these novel strategies together with the ever-increasing understanding of the complex pathophysiology of ARF, offers the promise of effective and more physiological therapeutic interventions in this new millennium. 相似文献
94.
《Expert opinion on investigational drugs》2013,22(12):1631-1640
Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cellular events such as proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and the alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biological and clinical activity in patients with prostate cancer has been demonstrated in a Phase III clinical setting by the suppression of markers of biochemical and clinical prostate cancer progression, and by a delay in time to disease progression, especially in patients with bone disease. 相似文献
95.
《Expert opinion on pharmacotherapy》2013,14(12):2047-2060
The original definition of Eisenmenger syndrome refers to an unrestrictive post-tricuspid valve congenital systemic-to-pulmonary shunt. When the pulmonary arterial systolic pressure becomes equal to the systemic arterial systolic pressure, the direction of the shunt becomes pulmonary-to-systemic. The latter leads to progressive cyanosis, and exercise intolerance is initially proportional to the degree of hypoxaemia. Later, congestive heart failure may occur. The management principle is to avoid any factors that destabilise this delicately balanced physiology. Until recently, this could only be achieved by symptomatic therapy; however, when patients are severely incapacitated, transplantation is needed. At present, new drugs, which are more selective pulmonary vasodilators, are available to interfere with the ongoing disease process to improve functional capacity and delay the decision for transplantation. 相似文献
96.
《Expert opinion on investigational drugs》2013,22(11):1761-1763
Clazosentan (Ro 61-1790, VML-588 or AXV-034) is under study in clinical trials for the treatment of patients with aneurysmal subarachnoid hemorrhage (SAH) by Actelion Pharmaceuticals. It is a synthetic endothelin (ET) A receptor antagonist that decreases and reverses cerebral vasospasm after experimental SAH. Remarkable dose-dependent effects were observed on angiographic vasospasm in the CONSCIOUS-1 human clinical trial, supporting proceeding with a Phase III clinical trial. This study (CONSCIOUS-2) will enroll approximately 765 patients randomized 2:1 to clazosentan 5 mg/h intravenously or placebo. All patients will undergo neurosurgical aneurysm clipping and outcome will be assessed primarily based on mortality and vasospasm-related morbidity. 相似文献
97.
《Expert opinion on emerging drugs》2013,18(2):377-388
Hypertension is a global health problem, affecting developing and developed countries alike. Most patients with hypertension are undiagnosed, and most diagnosed patients are either untreated or inadequately treated. Randomised controlled trial evidence suggests diuretic therapy for hypertension is as effective as newer drugs in reducing cardiovascular events. There is good evidence for the use of specific classes of drugs in hypertensive patients with a variety of associated clinical conditions, but for uncomplicated cases, the current emphasis in hypertension management is on blood pressure lowering rather than drug class. Individual patients vary in their responses to different drug classes, and optimal therapy for the individual is determined by trial and error. Pharmacogenomics may assist in tailoring therapy for individuals in the future. Emerging drugs include newer members of classes already established in clinical practice, for example, angiotensin II receptor antagonists, aldosterone receptor antagonists, calcium antagonists and centrally acting drugs; newer fixed-dose combination therapies; and more novel therapies, for example, endothelin (ET) receptor antagonists, activators of nitric oxide (NO)-sensitive guanylyl cyclase and vasopeptidase inhibitors. 相似文献
98.
Robert P. Ostrowski Zdzisawa Kowalska Sawomir Jauszewski Andrzej Kapuciski 《Drug development research》2005,64(3):137-144
In previous studies, bosentan was found to decrease plasma leptin concentrations after myocardial infarction (MI) in rats and had decreased mortality. The present study was undertaken to examine the effect of bosentan on leptin and endothelin‐1 (ET‐1) concentrations in plasma and ET‐1 concentrations in the hippocampus after cardiac arrest (CA) in rats. Studies were performed in 72 rats divided into treated and untreated animals in the following experimental groups: control, 3 min, 10 min, 1 h, 24 h, and 7 days after CA. Bosentan was given daily 2 h before CA or decapitation, 7 days, by gavage at a dose of 100 mg/kg. Plasma leptin concentration decreased in the early period after CA, and being elevated in 24 h, normalized 1 week later. Bosentan kept plasma leptin concentration at the control level in the postischemic period. Plasma ET‐1 concentration significantly increased during the postischemic period. Bosentan produced the elevation of plasma ET‐1 concentration in the preischemic period and kept the level of ET‐1 at control values after CA. Concentration of ET‐1 in the hippocampus was significantly lower 24 h after CA and was elevated after 1 week. The most dramatic effect of bosentan on ET‐1 concentration was in the hippocampus, where it significantly decreased during the entire postischemic recovery period. We postulate an important effect of bosentan on concentration of ET‐1 and leptin in plasma and ET‐1 in the brain after global cerebral ischemia caused by CA. Drug Dev Res 64:137–144, 2005. © 2005 Wiley‐Liss, Inc. 相似文献
99.
高氧液对脑缺血大鼠内皮素及降钙素基因相关肽含量的影响 总被引:7,自引:0,他引:7
目的 :探讨高氧液对缺血大鼠脑细胞的保护作用。方法 :40只 Wistar大鼠 (雌雄各半 )随机分成高氧液组、对照组、模型组和假手术组 ,每组各 10只。阻断 3条动脉造成急性不完全性脑缺血 ,制备动物模型。制模成功后 ,高氧液组立即以 10 ml· kg- 1 · h- 1 的速率经尾静脉输入高氧液 ,对照组以同种方法输入等量生理盐水 ,模型组和假手术组不治疗。制模后 1小时各组动物经腹主静脉取血 ,然后立即断头取脑 ,测定内皮素 (ET)和降钙素基因相关肽 (CGRP)含量。结果 :高氧液可明显降低脑缺氧后 ET水平 ,而升高 CGRP水平 ,纠正 ET、CGRP失衡。结论 :高氧液对缺血大鼠脑细胞有明显保护作用。 相似文献
100.
Sawako Unezaki Tayo Katano Takeshi Y. Hiyama Nguyen H. Tu Satoru Yoshii Masaharu Noda Seiji Ito 《The European journal of neuroscience》2014,39(5):720-729
Nax, a sodium concentration‐sensitive sodium channel, is expressed in non‐myelinating Schwann cells of the adult peripheral nervous system, but the pathophysiological role remains unclear. We found that functional recovery of the hind paw responses from the sciatic nerve transection was delayed in Nax knockout ( ) mice. Histological analyses showed a decrease in the number of regenerated myelinated axons in sciatic nerves. The delay in the recovery in mice was improved by lactate and inhibited by a monocarboxylate transporter inhibitor. In vitro experiments using cultured Schwann cells showed that lactate release was enhanced by endothelin (ET)‐1 and blocked by an ET receptor type B antagonist. Here, it is conceivable that Nax was activated by ET‐1. The amount of lactate release by ET‐1 was lower in mice than in wild‐type mice. These results indicated that Nax is functionally coupled to ET for lactate release via ET receptor type B and is involved in peripheral nerve regeneration. 相似文献